Olmesartan Medoxomilo + Hidroclorotiazida Alter (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil combined with hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system to lower blood pressure. Indicated indications include:

• Hypertension: improves blood pressure control when monotherapy is insufficient.
• Hypertensive urgency: assists in achieving target pressures more rapidly under medical supervision.
• Diastolic heart failure with fluid overload: reduces preload and afterload, aiding symptom management.
• Chronic kidney disease with hypertension: slows progression by controlling systemic pressure.
• Post‑myocardial infarction hypertension: helps maintain optimal hemodynamics after an event.

• Olmesartan medoxil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II‑mediated vasoconstriction, aldosterone release, and sympathetic activation. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting natriuresis and diuresis, which together lower intravascular volume and systemic vascular resistance, resulting in reduced blood pressure.

Olmesartan medoxil with hydrochlorothiazide may cause a range of adverse reactions.

Common Side Effects

• Dizziness: light‑headed sensation, especially after standing.
• Headache: mild to moderate intensity.
• Fatigue: general feeling of tiredness.
• Electrolyte imbalance: low potassium or sodium levels.
• Increased urination: due to the diuretic component.
• Mild gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects

• Severe hypotension: markedly low blood pressure requiring medical attention.
• Acute kidney injury: sudden decline in renal function.
• Hyperkalemia: elevated potassium levels, potentially life‑threatening.
• Angioedema: swelling of face, lips, tongue, or airway.
• Liver enzyme elevation: signs of hepatic stress.
• Blood dyscrasias: rare blood cell abnormalities.

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters.

• Renal function: assess baseline creatinine and eGFR, adjust if impaired.
• Electrolytes: check serum potassium and sodium before and during treatment.
• Pregnancy: avoid use; teratogenic risk is documented for ARBs.
• Concomitant drugs: review for additive potassium‑sparing or diuretic effects.
• Elderly patients: start with lower dose and monitor for orthostatic changes.
• Store at below 25°C: keep in the original container, protect from moisture and light.

Olmesartan medoxil with hydrochlorothiazide can interact with several drug classes, requiring clinical awareness.

Major Interactions (Avoid)

• Aliskiren: combined use in diabetes or renal impairment may increase risk of renal dysfunction.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyper‑kalemia.
• NSAIDs: can blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely)

• Lithium: may increase lithium levels, risking toxicity.
• Antidiabetic agents: enhanced glucose‑lowering effect may require dose adjustment.
• ACE inhibitors or other ARBs: additive blood pressure lowering and renal risk.
• Loop diuretics: may intensify volume depletion and electrolyte disturbances.
• Antidepressants (SSRIs): modest increase in hyponatremia risk.